US Patent 11,883,526: Esketamine Dosing-Regimen Claims, Exclusivity, Litigation and Generic-Entry Risk
US Patent 11,883,526 protects a specific Spravato-style esketamine regimen for major depressive disorder. Its core claim requires a four-week induction phase with twice-weekly intranasal dosing, followed by less frequent maintenance dosing. It also requires that a patient whose depression worsens after a missed maintenance treatment be returned to the previously higher treatment frequency.
The patent does not broadly cover all esketamine products, all intranasal formulations, or all depression treatment. Its commercial value is concentrated in the FDA-approved dosing algorithm for Spravato, particularly the missed-dose rescue protocol.
What does US Patent 11,883,526 cover?
The independent claim covers a method of treating major depressive disorder in a human patient using an aqueous intranasal esketamine formulation. The regimen must include all of the following elements:
| Claim element |
Required limitation |
| Disease |
Major depressive disorder |
| Patient |
Human patient in need of treatment |
| Dosage form |
Aqueous intranasal formulation |
| Active ingredient |
Esketamine or a pharmaceutically acceptable salt |
| Induction duration |
Four weeks |
| Induction dose |
About 56 mg or about 84 mg per session |
| Induction frequency |
Twice weekly |
| Maintenance dose |
About 56 mg or about 84 mg per session |
| Maintenance frequency |
Once weekly or once every other week |
| Missed-dose event |
Depression symptoms worsen after a missed maintenance session |
| Response to worsening |
Patient returns to the previously higher frequency |
The claim is a method-of-treatment claim rather than a composition claim. It does not require a particular device, container, preservative system, concentration, pH, excipient, or manufacturing process.
The claim also does not expressly require esketamine hydrochloride in its broadest form. That limitation appears in dependent claims 9, 11, 15, 17, 21, 23, 27, 29 and 33.
How do claims 1 through 33 differ?
Claims 2 and 3 define the two principal missed-dose pathways:
- Claim 2 requires return from once-weekly dosing to twice-weekly dosing.
- Claim 3 requires return from every-other-week dosing to once-weekly dosing.
Claims 4 and 5 add adjunctive antidepressant treatment. Claim 5 requires adjunctive antidepressant treatment during both induction and maintenance. Claim 6 narrows that treatment to an oral antidepressant.
Claims 7 and 8 identify two patient populations:
- Major depressive disorder with suicidal ideation or behavior.
- Treatment-resistant depression.
Claims 9 and later dependent claims specify esketamine hydrochloride. The remaining claims combine the dosing-frequency limitations with treatment-resistant depression, suicidal ideation or behavior, oral antidepressants, and esketamine hydrochloride.
The claim tree is heavily repetitive. Claims 10 through 33 create narrower combinations, but they do not introduce a different technical mechanism. They multiply potential claim sets across patient type, dosing interval, adjunctive therapy, and salt form.
What is the strongest limitation in US Patent 11,883,526?
The strongest limitation is the missed-treatment response requirement.
A potential infringement theory would need to establish more than intranasal esketamine use at 56 mg or 84 mg. It would need evidence that:
- The patient completed or entered the claimed four-week induction regimen.
- The patient was receiving maintenance treatment once weekly or every other week.
- A treatment session was missed.
- Depression symptoms worsened after the missed session.
- The patient was returned to the previously higher treatment frequency.
This patient-specific sequence creates an important evidentiary burden. A product label, clinical protocol, electronic treatment record, or prescriber instruction may establish the regimen, but proving the patient’s worsening symptoms and the provider’s response would remain central to an infringement case.
The claim is therefore commercially aligned with a clinical protocol, but it is narrower than a patent covering routine Spravato administration.
What formulations are protected by US Patent 11,883,526?
The patent claims an aqueous intranasal formulation comprising esketamine or a pharmaceutically acceptable salt. The claims do not require a specific excipient package or a particular concentration.
Dependent claims specifically identify esketamine hydrochloride. Spravato is an aqueous nasal spray containing esketamine hydrochloride and is administered as a 28 mg device, with 56 mg and 84 mg total doses delivered through multiple devices.[1]
The formulation language creates several boundaries:
- A nonaqueous formulation may fall outside the literal scope.
- An oral, injectable, or sublingual product is outside the claimed route.
- A formulation containing racemic ketamine rather than esketamine may fall outside the active-ingredient limitation.
- A formulation used under a different dosing schedule may avoid the regimen limitations.
- A competing product using the same esketamine hydrochloride nasal formulation could still avoid the claim if it does not practice the required missed-dose protocol.
The patent is not a broad formulation patent. Its formulation limitation supports the dosing method and links the claim to intranasal esketamine products.
When does US Patent 11,883,526 lose exclusivity?
The patent issued on January 30, 2024.[2] Its effective expiration is generally expected to track the earliest nonprovisional priority date in its patent family, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
Publicly available family information places the relevant esketamine method-of-treatment family in the mid-2010s priority period. A practical planning estimate is expiration in the mid-2030s, rather than the 20-year anniversary of the 2024 issue date.
The exact enforceable expiration should be determined from:
- The patent’s earliest effective nonprovisional filing date.
- Any continuation relationship.
- Patent-term adjustment shown on the USPTO record.
- Any terminal disclaimer.
- Any patent-term extension under 35 U.S.C. § 156.
A patent expiration date does not by itself establish generic launch timing. Other Orange Book-listed patents, regulatory exclusivity, injunctions, settlements, or separate formulation patents may control entry.
What is the FDA and Orange Book status of the patent?
Spravato, containing esketamine hydrochloride, received FDA approval in 2019 for treatment-resistant depression in conjunction with an oral antidepressant.[3] FDA later approved the product for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, also in conjunction with an oral antidepressant.[4]
The FDA label describes:
- Twice-weekly dosing during the four-week induction phase.
- Weekly dosing during the following maintenance period.
- Every-other-week or weekly dosing during later maintenance, depending on response.
- A return to the prior dosing frequency when symptoms worsen after missed treatment.[1]
Those label instructions materially overlap claim 1 and claims 2 and 3.
US Patent 11,883,526 is a method-of-use patent directed to treatment administration. If listed in the Orange Book for the relevant approved indication, an ANDA applicant seeking approval before patent expiration would generally need to address it through a Paragraph III or Paragraph IV certification, depending on the proposed launch date and the applicant’s legal position.[5]
Because the claim tracks labeled dosing instructions, a generic applicant could face a use-code and induced-infringement issue even if the proposed product is chemically equivalent to Spravato.
What generic entry risks exist for esketamine nasal spray?
The principal generic pathway is an ANDA for a product pharmaceutically equivalent and bioequivalent to Spravato. The applicant would need to address the reference product’s listed patents and applicable exclusivity.
Three entry strategies are possible:
| Strategy |
Commercial effect |
Patent risk |
| Full label including missed-dose instructions |
Broad indication and regimen access |
Highest risk under claims 1-33 |
| Carved-out label excluding protected use |
Earlier entry may be possible |
Risk of induced infringement if marketing promotes the protected regimen |
| Paragraph IV challenge |
Potential launch before patent expiration |
Litigation, 30-month stay risk, and possible injunction |
The patent’s vulnerability is linked to the fact that its core regimen was publicly reflected in the FDA label and clinical-development program. A challenger could examine written description, enablement, obviousness, anticipation, claim construction, and whether the claimed missed-dose response was adequately supported by the priority filing.
The patentee would argue that the claim captures a clinically specific sequence: symptom worsening after a missed maintenance treatment followed by restoration of the prior higher frequency. That sequence may be harder to invalidate than a claim covering only twice-weekly and weekly dosing, depending on the earlier disclosures.
Which companies are challenging the Spravato patent estate?
No reliable conclusion that a specific company has filed a Paragraph IV challenge to US Patent 11,883,526 can be drawn from the claim text alone. Patent litigation and ANDA-certification activity must be established from PACER, FDA litigation records, Orange Book updates, or company disclosures.
The relevant competitive field includes:
- Janssen Pharmaceuticals and Johnson & Johnson, associated with Spravato.
- Generic drug companies evaluating esketamine nasal-spray ANDAs.
- Specialty psychiatry companies developing alternative rapid-acting antidepressants.
- Developers of ketamine-based products using different routes or formulations.
A competing intranasal esketamine product would face the greatest risk if it uses the same 56 mg or 84 mg doses, the same four-week induction schedule, the same maintenance intervals, and labeling that directs restoration of a higher frequency after a missed session.
What patent litigation affects US Patent 11,883,526?
The principal litigation risk is likely to arise through an ANDA Paragraph IV action rather than through conventional product-liability or formulation litigation.
Potential causes of action include:
- Filing an ANDA with a Paragraph IV certification.
- Induced infringement through a proposed label.
- Contributory infringement based on product instructions or promotional materials.
- Declaratory judgment litigation over noninfringement or invalidity.
- Patent-term or Orange Book listing disputes.
The most important litigation issue would be whether a generic label alone induces performance of the missed-dose limitation. A generic company could argue that the claim requires individualized clinical facts not controlled by the manufacturer. The patentee could respond that the label instructs the physician to use the same treatment algorithm and that the relevant patient response is a foreseeable consequence of the labeled regimen.
How strong is the patent estate for Spravato?
The estate is stronger when viewed as a portfolio than when viewed through US Patent 11,883,526 alone.
| Protection category |
Strategic value |
| Active ingredient and esketamine stereochemistry |
Foundational, but generally older and more exposed to expiration |
| Intranasal aqueous formulation |
Important for product substitution and formulation equivalence |
| Dosing regimen |
Directly aligned with the approved label |
| Treatment-resistant depression |
Commercially central to Spravato |
| Suicidal ideation or behavior |
Separate indication value |
| Adjunctive oral antidepressant use |
Matches FDA labeling |
| Manufacturing and device protection |
Can complicate product development even after method claims weaken |
US Patent 11,883,526 has high label overlap but narrower claim breadth. Its strength depends on the validity of the priority disclosure and the ability to prove the patient-specific missed-dose sequence. It is less useful against a product that uses a different dosing regimen or avoids directing the claimed maintenance-rescue protocol.
How does Spravato compare with competing antidepressant products?
Spravato differs from conventional antidepressants because it is administered intranasally under a restricted distribution and monitoring system. It also differs from intravenous or compounded ketamine because the approved product, route, dose, monitoring framework, and FDA labeling are specific.
| Product or approach |
Route |
Main patent exposure |
| Spravato |
Intranasal esketamine |
Formulation, regimen, indication and device patents |
| Generic esketamine nasal spray |
Intranasal |
Orange Book patents and label-induced infringement |
| Compounded ketamine |
Usually intravenous, intramuscular, or oral |
Generally outside the intranasal claim, subject to facts |
| Conventional SSRIs/SNRIs |
Oral |
Not covered by the esketamine claims |
| Other rapid-acting antidepressants |
Varies |
Separate composition, formulation and method estates |
There is no biosimilar pathway for esketamine because it is a chemically synthesized small molecule. The relevant competitor pathway is generic substitution through an ANDA, not a 351(k) biosimilar application.
What commercial exposure does the patent create?
The patent’s value is tied to continued Spravato use in treatment-resistant depression and the product’s expansion into suicidal-ideation treatment. The claims cover the dosing behavior that supports chronic maintenance use, not merely the initial prescription.
Revenue exposure is therefore greatest for:
- Patients who remain on weekly maintenance.
- Patients transitioned to every-other-week maintenance.
- Patients requiring re-escalation after symptom worsening.
- Providers following the FDA label closely.
- Payers seeking substitution with an ANDA-approved product.
A generic that omits the protected use may not immediately capture the full market. A fully labeled generic would face greater litigation risk but could compete more directly for the maintenance population.
Key Takeaways
- US Patent 11,883,526 is a method-of-treatment patent, not a broad esketamine composition patent.
- Claim 1 requires a four-week, twice-weekly induction phase and a weekly or every-other-week maintenance phase.
- The critical limitation is worsening depression after a missed maintenance session followed by restoration of the prior higher frequency.
- Claims 2 and 3 define the two principal frequency-restoration pathways.
- Claims 4 through 33 add oral antidepressants, treatment-resistant depression, suicidal ideation or behavior, and esketamine hydrochloride.
- The claims closely track FDA-approved Spravato dosing instructions.
- Generic risk is highest for an ANDA with a full label covering the same dosing and missed-treatment protocol.
- There is no biosimilar pathway because esketamine is a small-molecule drug.
- The patent’s commercial importance is significant, but its patient-specific limitations may create noninfringement and proof issues.
- The complete exclusivity analysis requires review of the full patent family, Orange Book listings, terminal disclaimers, patent-term adjustment, and any Paragraph IV litigation.
FAQs
Can a generic esketamine product avoid US Patent 11,883,526 by using only weekly dosing?
Potentially. A product that omits the claimed induction phase, the every-other-week option, or the missed-dose restoration instructions may avoid literal infringement, although induced-infringement analysis would depend on the proposed label and marketing conduct.
Does claim 1 cover intravenous ketamine treatment?
No. Claim 1 requires intranasal administration of an aqueous formulation containing esketamine or a pharmaceutically acceptable salt. Intravenous racemic ketamine treatment does not satisfy those limitations on its face.
Does the patent require treatment with an oral antidepressant?
No. Oral or other adjunctive antidepressant treatment is required only by dependent claims 4 through 6 and related claims. It is not required by claim 1.
Does US Patent 11,883,526 cover the Spravato device itself?
No. The claims provided are method claims. They do not expressly claim the nasal-spray device, container, actuator, dose counter, or delivery mechanism.
Can a physician’s off-label dosing decision infringe the patent?
A physician’s conduct could raise method-of-treatment infringement issues if every claim limitation is practiced, but liability would depend on the specific facts, including the regimen, patient response, prescribing instructions, and applicable induced-infringement theories.
References
-
Janssen Pharmaceuticals, Inc. (2024). Spravato (esketamine hydrochloride) nasal spray prescribing information. U.S. Food and Drug Administration.
-
United States Patent and Trademark Office. (2024). United States Patent No. 11,883,526, Methods of treating depressive disorders with esketamine.
-
U.S. Food and Drug Administration. (2019, March 5). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic.
-
U.S. Food and Drug Administration. (2020, July 31). Spravato approval for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
